SOLCITINIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H23N5O2
Molecular Weight	389.4503
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(NC(=O)C5CC5)=NN34

InChI

InChIKey=MPYACSQFXVMWNO-UHFFFAOYSA-N

InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)

HIDE SMILES / InChI

Molecular Formula	C22H23N5O2
Molecular Weight	389.4503
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.fiercebiotech.com/partnering/glaxosmithkline-hits-brakes-on-an-anti-inflammatory-drug-from-galapagos

Solcitinib (also known as GSK2586184 or GLPG0778) is a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriasis, lupus, and ulcerative colitis. Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. It was reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect. And an exploratory Phase I/II of the same drug for ulcerative colitis was put on hold as investigators review the program.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tyrosine-protein kinase JAK1 39 Target ID: CHEMBL2835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=25724932	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Systemic lupus erythematosus 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01777256	Palliative		Phase II 1147	Unknown Approved Use Unknown
Psoriasis 87 Sources: https://clinicaltrials.gov/ct2/show/NCT01782664	Palliative		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
779.8 ng/mL EXPERIMENT https://s3.amazonaws.com/ctr-gsk-7381/117171/efaf9f51-b67c-4381-a287-1d4fd566eb6e/df2d37af-3eb3-4e7b-9c87-e5b9e2b74657/117171-Clinical-Study-Result-Summary-v1.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLCITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1871.7 ng/mL EXPERIMENT https://s3.amazonaws.com/ctr-gsk-7381/117171/efaf9f51-b67c-4381-a287-1d4fd566eb6e/df2d37af-3eb3-4e7b-9c87-e5b9e2b74657/117171-Clinical-Study-Result-Summary-v1.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLCITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
4787.7 μg × h/L EXPERIMENT https://s3.amazonaws.com/ctr-gsk-7381/117171/efaf9f51-b67c-4381-a287-1d4fd566eb6e/df2d37af-3eb3-4e7b-9c87-e5b9e2b74657/117171-Clinical-Study-Result-Summary-v1.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	SOLCITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7546.1 μg × h/L EXPERIMENT https://s3.amazonaws.com/ctr-gsk-7381/117171/efaf9f51-b67c-4381-a287-1d4fd566eb6e/df2d37af-3eb3-4e7b-9c87-e5b9e2b74657/117171-Clinical-Study-Result-Summary-v1.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	SOLCITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7656.32 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27055521	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOLCITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
9.7 h EXPERIMENT https://s3.amazonaws.com/ctr-gsk-7381/117171/efaf9f51-b67c-4381-a287-1d4fd566eb6e/df2d37af-3eb3-4e7b-9c87-e5b9e2b74657/117171-Clinical-Study-Result-Summary-v1.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLCITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.8 h EXPERIMENT https://s3.amazonaws.com/ctr-gsk-7381/117171/efaf9f51-b67c-4381-a287-1d4fd566eb6e/df2d37af-3eb3-4e7b-9c87-e5b9e2b74657/117171-Clinical-Study-Result-Summary-v1.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLCITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008U3T	https://www.1pchem.com/search?query=1P008U3T
AChemBlock	L13479	http://www.achemblock.com/catalogsearch/result/?q=L13479
Ambeed	A119338	http://www.ambeed.com/search/Search.html?keyword=A119338
Angene	AGN-PC-0WCXBS	http://www.angenechemical.com/productshow/AGN-PC-0WCXBS.html
AstaTech	42240	http://astatechinc.com/CPSResult.php?CRNO=42240
Axon MedChem	2539	https://www.axonmedchem.com/product/2539
BLD Pharm	BD300983	http://www.bldpharm.com/search/Search.html?keyword=BD300983
Chem Scene	CS-5204	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5204
ChemShuttle	157321	https://www.chemshuttle.com/catalogsearch/result/?q=157321
eMolecules	56747963	https://orderbb.emolecules.com/search/#?query=56747963
Excenen	EX-A2326	http://www.excenen.com/searchresultlist.php?id=EX-A2326
Fluorochem	497231	http://www.fluorochem.co.uk/Products/Product?code=497231
KeyOrganics	AS-56075	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56075
Lab Network	LN01344106	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01344106
mcule	MCULE-3437951506	https://mcule.com/MCULE-3437951506/
MedChem Express	HY-16755	https://www.medchemexpress.com/search.html?q=HY-16755&ft=&fa=&fp=
Molnova	M10753	https://www.molnova.com/en/serch-list.html?keywords=M10753
MolPort	MolPort-039-136-931	https://www.molport.com/shop/molecule-link/MolPort-039-136-931
TargetMol	T3620	https://www.targetmol.com/search?keyword=T3620

Patents

Sample Use Guides

In Vivo Use Guide

at doses of 50 mg twice daily (b.i.d), 100 mg b.i.d, 200 mg b.i.d, 400 mg b.i.d up to 12 weeks

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:00:29 GMT 2025` Edited by `admin` on `Mon Mar 31 22:00:29 GMT 2025`
Record UNII	3V7GQ1260K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SOLCITINIB

Official Name

English

solcitinib [INN]

Preferred Name

English

CYCLOPROPANECARBOXAMIDE, N-(5-(4-((3,3-DIMETHYL-1-AZETIDINYL)CARBONYL)PHENYL)(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)-

Systematic Name

English

GLPG-0788

Code

English

Solcitinib [WHO-DD]

Common Name

English

GSK-2586184

Code

English

GLPG-0778

Code

English

G-154578

Code

English

GLPG0778

Code

English

GSK-2586184A

Code

English

SOLCITINIB [USAN]

Common Name

English

GSK2586184A

Code

English

G154578

Code

English

N-(5-(4-((3,3-DIMETHYL-1-AZETIDINYL)CARBONYL)PHENYL)(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)CYCLOPROPANECARBOXAMIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1967